» Articles » PMID: 3404985

The Synthesis and Biological Activity of 25-hydroxy-26,27-dimethylvitamin D3 and 1,25-dihydroxy-26,27-dimethylvitamin D3: Highly Potent Novel Analogs of Vitamin D3

Overview
Specialty Biochemistry
Date 1988 Aug 1
PMID 3404985
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We synthesized 25-hydroxy-26,27-dimethylvitamin D3, 9, and 1,25-dihydroxy-26,27-dimethylvitamin D3, 14, from chol-5-enic acid-3 beta-ol and tested their biological activity in vivo and in vitro. 9 was found to be highly potent vitamin D analog with bioactivity similar to that of 25-hydroxyvitamin D3. 9 bound to rat plasma vitamin D binding protein with approximately one-third the affinity of 25-hydroxyvitamin D3. In a duodenal organ culture system and in a competitive binding assay with chick intestinal 1,25-dihydroxyvitamin D receptor, 9 was significantly more potent than 25-hydroxyvitamin D3. 1,25-Dihydroxy-26,27-dimethylvitamin D3, 14 was also highly active in vivo. At doses of 1000-5000 pmol/rat, its action was more sustained than that of 1,25-dihydroxyvitamin D3. 14 bound to vitamin D binding protein about 18 times less effectively than 1,25-dihydroxyvitamin D3. 14 bound to the chick intestinal cytosol receptor with an affinity one-half that of 1,25-dihydroxyvitamin D3. In a duodenal organ culture system, 14 was about half as active as 1,25-dihydroxyvitamin D3. Extension of the sterol side chain, at C-26 and C-27, by methylene groups, prolongs the bioactivity of a vitamin D sterol hydroxylated at C-1 and C-25; the corresponding sterol, hydroxylated only at C-25, does not show any alteration of its bioactivity in vivo. These newly synthesized analogs may potentially be of therapeutic use in various mineral disorders.

Citing Articles

In Vitro Anti-Oxidant, In Vivo Anti-Hyperglycemic, and Untargeted Metabolomics-Aided-In Silico Screening of Macroalgae Lipophilic Extracts for Anti-Diabetes Mellitus and Anti-COVID-19 Potential Metabolites.

Sunarwidhi A, Rahmaniar W, Prasedya E, Padmi H, Widyastuti S, Pangestu K Metabolites. 2023; 13(12).

PMID: 38132859 PMC: 10745437. DOI: 10.3390/metabo13121177.


Novel oxysterols observed in tissues and fluids of AY9944-treated rats: a model for Smith-Lemli-Opitz syndrome.

Xu L, Liu W, Sheflin L, Fliesler S, Porter N J Lipid Res. 2011; 52(10):1810-20.

PMID: 21817059 PMC: 3173002. DOI: 10.1194/jlr.M018366.


Calcium regulating activity of 24a-homo-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3 and 26,27-dimethyl-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3.

Harada M, Miyahara T, Miyata M, Komiyama H, Sugure A, Ikemoto Y Calcif Tissue Int. 1993; 53(5):318-23.

PMID: 8287319 DOI: 10.1007/BF01351836.


Elongation of the side chain of analogs of 1 alpha,25-dihydroxyvitamin D3 prevents osteopenia in a rat model.

Harada M, Takamura T, Kozakai A, Miyahara T, Kozuka H, Ikekawa N Calcif Tissue Int. 1995; 56(3):220-6.

PMID: 7750028 DOI: 10.1007/BF00298614.


Calcium regulating activity of 26,27-dialkyl analogs of 1 alpha,25-dihydroxyvitamin D3.

Miyahara T, Harada M, Miyata M, Sugure A, Ikemoto Y, Takamura T Calcif Tissue Int. 1992; 51(3):218-22.

PMID: 1330237 DOI: 10.1007/BF00334550.